The Alliance submitted comments to the FDA draft guidance "Homologous Use of Human Cells, Tissues, and Cellular and Tissue-Based Products." Comments identified specific areas of the regulation that needed additional clarity and alignment across guidances in order to make them clinically meaningful, accurate, and consistent with - rather than contradictory to - existing regulations.

Read More